Skip to main content
. 2022 Dec 15;9:926064. doi: 10.3389/fcvm.2022.926064

Table 1.

Baseline characteristics for Allo-HCT and Control participants who completed baseline and follow-up assessments.

Allo-HCT Control
(n = 17) (n = 12)
Sex, % male 70% 42%
Age, years 45 ± 18 43 ± 13
Weight, kg 80.7 ± 18.0 74.3 ± 14.4
Body mass index, kg.m −2 27.4 ± 6.2 24.6 ± 3.7
Cardiovascular function
LVEF, % 54.7 ± 5.5* 59.5 ± 5.7*
GLS, % −17.8 ± 2.0* −20.0 ± 2.4
CI Reserve, L.min−1.m−2 3.8 ± 1.4** 5.9 ± 1.7
VO2peak, ml.kg−1.min−1 22.9 ± 8.0*** 34.8 ± 8.1
VO2peak, % predicted 67 ± 12*** 104 ± 16
Functional disability, n (%) 5 (29) 0 (0)
Cardiovascular risk factors, n (%)
Hypertension 4 (24) 0 (0)
Hyperlipidaemia 2 (12) 0 (0)
Diabetes 1 (6) 0 (0)
Body mass index ≥25 kg.m−2 9 (53) 5 (42)
Previous cardiovascular event 2 (12) 0 (0)
≥1 cardiovascular risk factor 10 (59) 5 (42)
Cardiovascular medications, n (%)
Statin/Cholesterol absorption inhibitor 1 (6) 0 (0)
Antihypertensives 2 (12) 0 (0)
Beta–blocker 1 (6) 0 (0)
Antidiabetic 1 (6) 0 (0)
Non–steroidal anti–inflammatory 3 (18) 1 (8)
Diagnosis, n (%)
Acute myeloid leukemia 11 (65) n/a
Non–Hodgkin lymphoma 3 (18) n/a
Acute lymphoblastic leukemia 2 (12) n/a
Myelodysplasia 1 (6) n/a
Prior cancer treatment, n (%)
No prior treatment 1 (6) n/a
Chemotherapy 16 (94) n/a
 Cumulative anthracycline dose, mg.m−2 180 (100−270) n/a
Targeted Therapy 5 (29) n/a
Immunotherapy 3 (18) n/a
Radiation 2 (12) n/a
Autologous stem cell transplant 1 (6) n/a

Data are mean ± SD, median (IQR) or n (%). CI, cardiac index; GLS, global longitudinal strain; LVEF, left-ventricular ejection fraction; VO2peak, peak oxygen uptake. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control.